That’s a wrap on #ESCMIDGlobal2026 in Munich!

Thank you – your science, energy and engagement brought this unforgettable congress to life.

See you next year in Stockholm for ESCMID Global 2027!

CME credits are available – survey opens at 16:00!

Log in to the CME platform with your ESCMID account to claim points for each session and complete the general survey to receive your certificate. The survey remains open until 21 October 2026.

ESCMID and EMA leaders met again today at #ESCMIDGlobal2026 to discuss future collaborations and the importance of connecting evidence-based science with policy and regulations around medicines.
European Medicines Agency #IDSky

Save the date! 📍

ESCMID Global 2027 will be held in Stockholm, Sweden, from 9–13 April 2027, once again bringing together our global community for another year of science, collaboration and exchange.

Become an ESCMID member! 🌍

ESCMID welcomes experts in #clinicalmicrobiology and #infectiousdiseases from all countries and career stages, with a strong focus on inclusiveness and parity.

Join or renew your membership any time through a simple, year-round process.

That’s a wrap on Clinical Grand Rounds at #ESCMIDGlobal2026: 7 cases, global perspectives and much debate – a reminder that clinical decisions are rarely straightforward. Did you hear anything you’ll take into practice?

Enjoy the final day of the congress! #infectiousdiseases

Tom Cartau presents a destructive spondylodiscitis with abscesses, negative cultures and a diagnostic dead end. Yoav Keynan and David Lebeaux called it early: echinococcosis. 🤖 “Dr Al Gorithm” went broad: brucella, Q fever, Pott’s.
🏆 Humans win this round. #ESCMIDGlobal2026

Paul Chabert presents at #ESCMIDGlobal2026 Clinical Global Rounds: a chronic “Caledonian rash” evolving over 20 years, with widespread plaques and no systemic features. Priscilla Rupali nailed it before “Dr Ann Thropic” (🤖 #AI). It was Mycobacterium marinum.

Last chance to get your photo 📸

The Photo Booth closes at 14:00 CEST – make sure you stop by before it shuts to capture your #ESCMIDGlobal2026 memories!

Johanna Erber presents at #ESCMIDGlobal2026 Clinical Global Rounds: high fever (41.5°C), severe headache, hepatomegaly, cytopenias, rising LFTs + haemolysis after travel to Vietnam with mosquito exposure. Dengue? Zika? Salmonella? Staph/Strep? What’s your call? Let us know below.

Lauren Saint presents a complex case: progressive vision loss, polyarthropathy, violaceous nodules + 3 cm foot abscess. What do you suspect? Experts considered Brucella suis or #HIV. Final diagnosis? Sporothrix schenckii complex. #infectiousdiseases #ESCMIDGlobal2026

David Paterson weighs in on the next case: oral ulcers, unilateral weakness and a thalamic lesion – a complex neuro-infectious picture. David leans toward parasites, mycobacteria or fungi. Where would you go next? #infectiousdiseases #ESCMIDGlobal2026

Samuel Showalter (US) presents a multi-organ puzzle: fever, weight loss, cholestasis, lung nodules, fascial oedema. Despite denying sexual activity, Yoav Keynan suspects #HIV or #syphilis. Final diagnosis: secondary syphilis with multi-organ involvement. #ESCMIDGlobal2026

The final day of #ESCMIDGlobal2026 is here!

Look back at yesterday’s Daily Highlights and get ready for a day packed with standout sessions and moments you won’t want to miss.

www.escmid.org/congress-events/escmid-g...

We also said farewell to Annelies Zinkernagel and Anu Kantele who will leave the Executive Committee and will be replaced by incoming members Luigia Scudeller and Silvio Brugger! Thank you to all and congratulations to the new members!

Last night at the ESCMID Assembly of Members we inaugurated our new president, Jon S. Friedland. We extend our thanks to Robert Skov for his years of service and look forward to his new role as past president. At the same time we give a very warm welcome to Jon as he steps into this new role.

Rotem Gorfinkel (Israel) kicks off Clinical Grand Rounds at #ESCMIDGlobal2026 with a complex case of mistaken identity. Skin lesions, travel history and broad animal exposures – Nina Khanna suggests biopsy and exploring fungal infection. #infectiousdiseases

Heading to Clinical Grand Rounds at #ESCMIDGlobal2026 in Hall ICM 14? Starting now: 7 complex #infectiousdiseases, presented by trainees and discussed by 6 global experts. Would you make the same clinical decisions? Chaired by Robert Read.
#MedEd

How would you approach the toughest #infectiousdisease cases?

One hour to go - put your thinking to the test on the final day of #ESCMIDGlobal2026 as the Clinical Grand Rounds dives into complex cases shared by six renowned experts!

“This Year in Public Health” at #ESCMIDGlobal2026:

💉 Vaccines are evolving beyond prevention
🧬 Personalized cancer vaccines activating durable T cell responses
🦠 Next-gen vaccines targeting AMR threats like Klebsiella

The vaccine landscape is rapidly expanding—from infection → cancer → resistance.

“This Year in Public Health” at #ESCMIDGlobal2026:

⚔️ War accelerates AMR
🏥 Strained systems + disrupted surveillance
🦠 Resistance spreads across care networks

A hidden consequence of conflict—and a growing threat.

💊 Antibiotic overuse costly (€2.7B EU)
💶 Stewardship = low cost, high return
💉 High-dose flu: modest benefit
🦟 Wolbachia → promising dengue control

Bottom line: Progress is real—but unequal, fragile, and system-driven
3/3

Happening now at #ESCMIDGlobal2026 — fireside chat with Dr. Charles Holmes on virus origin, evolution & the next pandemic

🧬 Spillover drives emergence
🌍 Connectivity accelerates spread
⚠️ Not if—but which virus, and when

Happening now at #ESCMIDGlobal2026

"Late-breaking research from The Lancet: new interventions for more established pathogens"

Late-breaking research at #ESCMIDGlobal2026

The SCOUT RCT in women with uncomplicated UTI challenges how we think about short-course antibiotics vs single-dose fosfomycin.

💊 Pragmatic, multicentre data
🌍 Real-world European settings
⚖️ Implications for stewardship

Next up at the #Lancet session here at #ESCMIDGlobal2026

H5 spillover is increasing—but the key question is immunity.

🦠 Frequent spillover: poultry → mammals → humans (no sustained transmission)
⚠️ Pandemic risk hinges on spread in an immunologically naïve population

👉 Are we more vulnerable than we think? #ESCMIDGlobal2026

Next up at #ESCMIDGlobal2026

🧬 Whole genome sequencing–guided precision medicine for rifampicin-resistant TB (SMARTT trial)

🎯 Goal: tailor therapy → shorten treatment

A major step toward individualized TB care 👀

SMARTT trial population:

👥 204 adults with pulmonary RR-TB
⚖️ Balanced arms: SoC (n=101) vs WGS (n=103)
📊 mITT: 78 vs 84

⚠️ High-risk cohort:
• HIV+: 73%
• Underweight (BMI <18.5): 59%
• RR/MDR-TB: 88%

Real-world, vulnerable population → results highly relevant for high-burden settings 🌍

📊 Clinical effectiveness (WGS vs SoC)

• ↓ Unfavourable outcomes by 18.4%
• Significant: non-inferior and superior

Bottom line: WGS-guided treatment improves outcomes.